PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
74.40%
Cash & equivalents growing 74.40% while TRAW's declined -23.96%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
74.40%
Below half of TRAW's -23.96%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.06%
Higher Other Current Assets Growth compared to TRAW's zero value, indicating worse performance.
70.82%
Below half of TRAW's -18.47%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.82%
Below half of TRAW's -18.15%. Michael Burry sees a potential red flag for stagnation or capital shortage.
72.56%
Above 1.5x TRAW's 3.94%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-50.51%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.03%
Less than half of TRAW's -96.12%. David Dodd sees fewer expansions in other current obligations.
36.12%
Less than half of TRAW's -52.86%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.12%
Less than half of TRAW's 442.63%. David Dodd sees far fewer liability expansions relative to competitor.
10.25%
Less than half of TRAW's -83.12%. David Dodd sees fewer share issuances vs. competitor.
-4.93%
0.5-0.75x TRAW's -6.86%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
247.64%
Below half TRAW's -712.94%. Michael Burry sees potential underperformance in building shareholder capital.
70.82%
Below half TRAW's -18.15%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-50.51%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
-77.35%
Less than half of TRAW's 23.96%. David Dodd sees better deleveraging or stronger cash buildup than competitor.